169 related articles for article (PubMed ID: 12600223)
1. Ontario's formulary committee: how recommendations are made.
PausJenssen AM; Singer PA; Detsky AS
Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
[TBL] [Abstract][Full Text] [Related]
2. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
Anis AH; Rahman T; Schechter MT
Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
[TBL] [Abstract][Full Text] [Related]
3. Incorporating economic evaluations into decision-making: the Ontario experience.
Laupacis A
Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
[TBL] [Abstract][Full Text] [Related]
4. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
Langley PC
Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
[TBL] [Abstract][Full Text] [Related]
5. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
Aspinall SL; Good CB; Glassman PA; Valentino MA
Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
[TBL] [Abstract][Full Text] [Related]
6. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
7. Quality of clinical and economic evidence in dossier formulary submissions.
Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
[TBL] [Abstract][Full Text] [Related]
8. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
9. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
Lexchin J
Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
[TBL] [Abstract][Full Text] [Related]
10. A call for fairness in formulary decisions.
Levinson W; Laupacis A
Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
[No Abstract] [Full Text] [Related]
11. Managed care guidelines for the economic evaluation of pharmaceuticals.
Langley PC; Martin RE
Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
13. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
Lipsy RJ
Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.
Detsky AS
Pharmacoeconomics; 1993 May; 3(5):354-61. PubMed ID: 10146886
[TBL] [Abstract][Full Text] [Related]
15. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
16. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
Lexchin J; Mintzes B
Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
[TBL] [Abstract][Full Text] [Related]
17. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
Neumann PJ
Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
[TBL] [Abstract][Full Text] [Related]
18. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
West R; Borden EK; Collet JP; Rawson NS; Tonks RS
Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
[TBL] [Abstract][Full Text] [Related]
19. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
Spooner JJ; Gandhi PK; Connelly SB
J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluations in the canadian common drug review.
Laupacis A
Pharmacoeconomics; 2006; 24(11):1157-62. PubMed ID: 17067199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
